Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin CH0012032048
Ticker ROG.VX
Company ROCHE
Currency CHF
Price
Aware Investor Index (AII) 171.6145
Recommendation STRONG BUY
P/E 8.69
ROE 31.75 %
Capitalization 82,609,266,992 $
Dividend Yield 8.92 %
P/S 1.50
AII Position 28
P/E Position 44
ROE Position 90
Capitalization Position 106
Dividend Yield Position 24
Sales 53,299,000,000 CHF
10-Year Average Earnings 9,210,600,000 CHF
Shares Outstanding 860,000,000
Equity 29,007,000,000 CHF
Dividend per Share 8.3 CHF
Industry Pharmaceutical
Country Switzerland
ROCHE Investor Relations Web Site http://www.roche.com/investors.htm







Sales:

YEAR MONTH AMOUNT
2017 12 53,299,000,000.00 CHF
2016 12 50,576,000,000.00 CHF
2015 12 48,145,000,000.00 CHF
2014 12 47,462,000,000.00 CHF
2013 12 46,780,000,000.00 CHF

Earnings:

YEAR MONTH AMOUNT
2017 12 8,825,000,000.00 CHF
2016 12 9,733,000,000.00 CHF
2015 12 8,863,000,000.00 CHF
2014 12 9,332,000,000.00 CHF
2013 12 11,164,000,000.00 CHF
2012 12 9,427,000,000.00 CHF
2011 12 9,343,000,000.00 CHF
2010 12 8,666,000,000.00 CHF
2009 12 7,784,000,000.00 CHF
2008 12 8,969,000,000.00 CHF

Equity:

YEAR MONTH AMOUNT
2017 12 29,007,000,000.00 CHF
2016 12 26,402,000,000.00 CHF
2015 12 23,300,000,000.00 CHF
2014 12 21,558,000,000.00 CHF
2013 12 21,241,000,000.00 CHF
2012 12 16,728,000,000.00 CHF
2011 12 14,482,000,000.00 CHF

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 860,000,000
2016 12 860,000,000
2015 12 862,000,000
2014 12 863,000,000
2013 12 863,000,000
2012 12 848,000,000
2011 12 849,000,000

 












Bloomberg News for ROCHE:



Google News for ROCHE:

Business Insider - 25 Feb 2019
Pharma giant Roche just bought biotech firm Spark, the maker of an ...
Swiss pharmaceutical company Roche is set to purchase US gene therapy company Spark Therapeutics for approximately $4.8 billion.
Investor's Business Daily - 25 Feb 2019
Get exclusive IBD analysis and action news daily.
"Although the price that Roche is paying for Spark seems steep, we see three potential rationales driving the deal," he said in a note to clients.
CNBC
Biogen Slips as Roche Spikes Alzheimer's Trials on Weak Data
Shares of Biogen Inc. came under pressure in trading before the U.S. market opened Wednesday after peer Roche Holding AG halted a pair of ...
Bloomberg - 30 Jan 2019
Selling Roche: Sector And Company-Specific Reasons
I took (modest) profits in Roche ADRs very recently, for industry-related and company-specific reasons. I suspect that many Big Pharma-Biotech ...
Seeking Alpha - 5 Feb 2019
Roche-AbbVie cancer drug gets accelerated FDA approval
(Reuters) - Roche Holding AG said on Wednesday its cancer drug, Venclexta, received accelerated approval from the U.S. Food and Drug ...
Reuters - 21 Nov 2018
Roche raises outlook for 2018 as new drugs gain traction
Swiss drugmaker Roche lifted its 2018 outlook on Thursday for the second time this year, after first-half sales and profit easily beat analyst ...
CNBC - 26 Jul 2018
מה דחף שלוש ענקיות רפואה להיכנס לריפוי גנטי?
החברות הן שתי הענקיות השווייצריות נוברטיס (סימול: NVS) ו-Roche Holding AG (סימול:RHHBY בארה"ב או ROG.VX בשווייץ) והשלישית, ביוג'ן (סימול: BIIB) ...
Bizportal - 7 Mar 2019
Roche eyes acquisition of Pacific Biosciences: sources
(Reuters) - Roche Holding AG ROG.VX has in recent weeks approached Pacific Biosciences of California Inc (PACB.O) to discuss acquiring the ...
Reuters - 2 Feb 2016
The Top 10 Biotechnology Companies (JNJ, ROG.VX)
Founded in Switzerland in 1896, Roche (NASDAQ: ROG.VX) calls itself the largest biotech company in the world, with 17 biopharmaceuticals ...
Investopedia - 22 Dec 2015
Roche buys privately-held GeneWEAVE BioSciences
ZURICH - Roche Holding AG (ROG.VX) Thursday said it has agreed to buy a U.S. microbiology diagnostic company in a deal which could rise ...


Back